Clinical care of two patients with Ebola virus disease in the United States

New England Journal of Medicine

Volumn 371, Issue 25, 2014, Pages 2402-2409

  Lyon, G Marshall ^a   Mehta, Aneesh K ^a   Varkey, Jay B ^a   Brantly, Kent ^c   Plyler, Lance ^c   McElroy, Anita K ^a,b   Kraft, Colleen S ^a   Towner, Jonathan S ^b   Spiropoulou, Christina ^b   Ströher, Ute ^b   Uyeki, Timothy M ^b   Ribner, Bruce S ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^c Samaritan's Purse   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ARTEMETHER PLUS BENFLUMETOL; ATOVAQUONE; GABAPENTIN; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; PARACETAMOL; PROGUANIL; RINGER LACTATE SOLUTION; MONOCLONAL ANTIBODY; NEW DRUG; VIRUS ANTIBODY; ZMAPP;

ABDOMINAL PAIN; ADULT; ANTIBODY DETECTION; ARTICLE; BLOOD TRANSFUSION; CASE REPORT; DIARRHEA; EBOLA HEMORRHAGIC FEVER; ELECTROLYTE DISTURBANCE; FEMALE; FEVER; FLUID THERAPY; GENERAL CONDITION IMPROVEMENT; HEMATEMESIS; HUMAN; HYPOVOLEMIA; INTERNATIONAL NORMALIZED RATIO; MACULOPAPULAR RASH; MALAISE; MALARIA; MALARIA RAPID TEST; MALE; MELENA; MIDDLE AGED; MYALGIA; PATIENT TRANSPORT; PERIPHERAL NEUROPATHY; PULSE OXIMETRY; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TACHYCARDIA; THROMBOCYTOPENIA; UNITED STATES; VIRUS LOAD; EBOLA VIRUS; EPIDEMIC; HEMORRHAGIC FEVER, EBOLA; IMMUNOLOGY; LIBERIA;

ADULT; ANTIBODIES, MONOCLONAL; ANTIBODIES, VIRAL; DISEASE OUTBREAKS; DRUGS, INVESTIGATIONAL; EBOLAVIRUS; FEMALE; HEMORRHAGIC FEVER, EBOLA; HUMANS; LIBERIA; MALE; MIDDLE AGED; UNITED STATES;

EID: 84912539210     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1409838     Document Type: Article

References (21)

1. Global alert and response: Ebola virus disease. Geneva: World Health Organization, 2014 (http://www.who.int/csr/don/archive/disease/ebola/en).
2. Ebola response roadmap situation report. Geneva: World Health Organization, 2014 (http://apps.who.int/iris/bitstream/10665/137510/1/roadmapsitrep-5Nov14-eng.pdf?ua-1).
3. Peters CJ. Marburg and Ebola virus hemorrhagic fevers. In: Mandell GL, Bennett JE, Dolin R, eds. Mandell, Douglas, and Bennett's principles and practices of infectious diseases. 7th ed. Philadelphia: Churchill Livingstone, 2010:2259-63.
4. Kortepeter MG, Bausch DG, Bray M. Basic clinical and laboratory features of filoviral hemorrhagic fever. J Infect Dis 2011;204:Suppl 3:S810-S816.
5. Feldmann H, Sanchez A, Geisbert TW. Filoviridae: Marburg and Ebola viruses. In: Knipe DM, Howley PM, eds. Fields virology. 6th ed. Philadelphia: Lippincott Williams & Wilkins, 2013:923-56.
6. Ebola haemorrhagic fever in Zaire, 1976. Bull World Health Organ 1978;56: 271-93.
7. MacNeil A, Farnon EC, Wamala J, et al. Proportion of deaths and clinical features in Bundibugyo Ebola virus infection, Uganda. Emerg Infect Dis 2010;16: 1969-72.
8. Wong G, Qiu X, Olinger GG, Kobinger GP. Post-exposure therapy of filovirus infections. Trends Microbiol 2014;22:456-63.
9. Del Rio C, Mehta AK, Lyon GM III, Guarner J. Ebola hemorrhagic fever in 2014: the tale of an evolving epidemic. Ann Intern Med 2014 August 19 (Epub ahead of print).
10. Qiu X, Wong G, Audet J, et al. Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp. Nature 2014;514:47-53.
11. Okware SI, Omaswa FG, Zaramba S, et al. An outbreak of Ebola in Uganda. Trop Med Int Health 2002;7:1068-75.
12. Bwaka MA, Bonnet MJ, Calain P, et al. Ebola hemorrhagic fever in Kikwit, Democratic Republic of the Congo: clinical observations in 103 patients. J Infect Dis 1999;179:Suppl 1:S1-S7.
13. Rollin PE, Bausch DG, Sanchez A. Blood chemistry measurements and Ddimer levels associated with fatal and nonfatal outcomes in humans infected with Sudan Ebola virus. J Infect Dis 2007;196:Suppl 2:S364-S371.
14. Seas C, Gotuzzo E. Vibrio cholerae. In: Mandell GL, Bennett JE, Dolin R, eds. Mandell, Douglas, and Bennett's principles and practice of infectious diseases. 7th ed. Philadelphia: Churchill Livingstone, 2010:2777-85.
15. Rao SSC, Summers RW, Rao GRS, et al. Oral rehydration for viral gastroenteritis in adults: a randomized, controlled trial of 3 solutions. JPEN J Parenter Enteral Nutr 2006;30:433-9.
16. Ksiazek TG, Rollin PE, Williams AJ, et al. Clinical virology of Ebola hemorrhagic fever (EHF): virus, virus antigen, and IgG and IgM antibody findings among EHF patients in Kikwit, Democratic Republic of the Congo, 1995. J Infect Dis 1999; 179:Suppl 1:S177-S187.
17. Sobarzo A, Ochayon DE, Lutwama JJ, et al. Persistent immune responses after Ebola virus infection. N Engl J Med 2013;369:492-3.
18. Mupapa K, Massamba M, Kibadi K, et al. Treatment of Ebola hemorrhagic fever with blood transfusions from convalescent patients. J Infect Dis 1999;179:Suppl 1:S18-S23.
19. WHO Blood Regulators Network. Position paper on collection and use of convalescent plasma or serum as an element in filovirus outbreak response. Geneva: World Health Organization, 2014 (http://www.who.int/bloodproducts/brn/brn-positionpaperconvplasmafiloviruses-finalweb14august2014.pdf).
20. Geisbert TW, Young HA, Jahrling PB, Davis KJ, Kagan E, Hensley LE. Mechanisms underlying coagulation abnormalities in Ebola hemorrhagic fever: overexpression of tissue factor in primate monocytes/macrophages is a key event. J Infect Dis 2003;188:1618-29.
21. McElroy AK, Erickson BR, Flietstra TD, et al. Ebola hemorrhagic fever: novel biomarker correlates of clinical outcome. J Infect Dis 2014;210:558-66.